A number of drugs included in the analysis are FDA approved for other cancer types (underlined in Figure 2C) and include the DHFR inhibitor methotrexate which has previously shown modest single agent activity in an unselected patient population with extensive stage SCLC [30]. The gene discussed is DHFR; the disease is small cell lung carcinoma.